Skip to main content

Table 1 Regression analysis for the outcomes

From: Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Outcomes Crude analysis p-value^^ Odds ratio (OR) (95%CI) p-value for adjusted analysis$**
Control group Tocilizumab group
Secondary infection (Bacterial/fungal), n (%) 214/476 (44.9) 132/261 (50.5) 0.14 1.34 (0.91, 1.94) 0.13
Resistant organisms (i.e. MDR, EDR, PDR), n (%) 82/141(58.1) 54/84 (64.2) 0.36 1.00 (0.51, 1.98) 0.99
CRE detection, n (%) 21/476 (4.4) 10/262 (3.8) 0.69 0.67 (0.29, 1.54) 0.34
  1. ^^Chi-square test is used to calculate the p-value
  2. $**Multivariable Logistic regression is used after adjusting for patient’s comorbidities (i.e. DM, CKD on dialysis), history of hospitalization or invasive procedure (Surgery) within 1 year, history of antibiotics exposure in the last 3 months, systemic corticosteroids during ICU and ICU LOS to calculate odds ratio and p-value